Abstract
Acute myeloid leukemia (AML) with t(8;21) is a heterogeneous disease. Although the detection of minimal residual disease (MRD), which is indicated by RUNX1-RUNX1T1 transcript levels, plays a key role in directing treatment, risk stratification needs to be improved, and other markers need to be assessed. A total of 66 t(8;21) AML patients were tested for aldehyde dehydrogenase (ALDH) activity by flow cytometry at diagnosis, and 52 patients were followed up for a median of 20 (1-34) months. The median percentage of CD34+ALDH+, CD34+CD38-ALDH+, and CD34+CD38+ALDH+ cells among nucleated cells were 0.028%, 0.012%, and 0.0070%, respectively. The CD34+ALDH+-H, CD34+CD38-ALDH+-H, and CD34+CD38+ALDH+-H statuses (the percentage of cells that were higher than the individual cutoffs) were all significantly associated with a lower 2-year relapse-free survival (RFS) rate in both the whole cohort and adult patients (P = .015, .016, and .049; P = .014, .018, and .032). Patients with < 3-log reduction in the RUNX1-RUNX1T1 transcript level after the second consolidation therapy (defined as MRD-H) had a significantly lower 2-year RFS rate than patients with ≥ 3-log reduction (MRD-L) (P = .017). The CD34+ALDH+ status at diagnosis was then combined...Continue Reading
References
Feb 17, 1994·Nature·T LapidotJ E Dick
Jul 1, 1997·Nature Medicine·D Bonnet, J E Dick
Aug 4, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R F SchlenkG Heil
Mar 26, 2005·Blood·Robert W StormsClayton A Smith
May 27, 2005·Stem Cells·Daniel J PearceDominique Bonnet
Aug 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciClara D Bloomfield
Sep 17, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anna van RhenenGerrit Jan Schuurhuis
Oct 20, 2005·Blood·Daniel J PearceDominique Bonnet
Dec 29, 2005·Blood·Dao-Pei LuKai-Yan Liu
Aug 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter PaschkaUNKNOWN Cancer and Leukemia Group B
Aug 31, 2006·British Journal of Haematology·Frederick R AppelbaumElihu H Estey
May 4, 2007·Leukemia·A M S CheungA Y H Leung
Mar 29, 2008·Cell Stem Cell·Christophe GinestierGabriela Dontu
Jun 5, 2008·Blood·David C TaussigDominique Bonnet
Oct 13, 2009·Experimental Hematology·Dan RanAnthony D Ho
Oct 14, 2009·Pharmacogenetics and Genomics·William J BlackVasilis Vasiliou
Jan 8, 2010·Blood·David C TaussigDominique Bonnet
Oct 5, 2010·Molecular Cancer Therapeutics·Charles N LandenAnil K Sood
Dec 2, 2010·Cancer Research·James P SullivanJohn D Minna
Aug 30, 2011·Nature Medicine·Kolja EppertJohn E Dick
Oct 26, 2011·Experimental Hematology·Dan RanAnthony D Ho
Jan 21, 2012·Blood·Jonathan M GerberRichard J Jones
Aug 10, 2012·Blood·John A Liu YinAlan K Burnett
Jan 17, 2013·Blood·Eric JourdanUNKNOWN French AML Intergroup
Mar 29, 2013·Blood·Hong-Hu ZhuXiao-Jun Huang
Dec 3, 2014·Leukemia Research·Ya-Zhen QinXiao-Jun Huang
Dec 30, 2014·International Journal of Cancer. Journal International Du Cancer·Van T HoangChristoph Lutz
Jan 29, 2016·Haematologica·Jonathan M GerberRichard J Jones
Mar 21, 2016·Leukemia Research·Hong-Hu ZhuXiao-Jun Huang
Jul 18, 2017·Gene·Xinlei GuoFang Liu
May 18, 2018·Neoplasia : an International Journal for Oncology Research·Katharina BlattPeter Valent
Aug 9, 2018·Blood Cancer Journal·Ya-Zhen QinXiao-Jun Huang
Oct 7, 2018·Leukemia·Bowen YanYi Qiu